查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836320

神經免疫學藥物市場，按產品類型、按適應症、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Neuroimmunology Drugs Market, By Product Type, By Indications, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年神經免疫學藥物市場規模價值 258.151 億美元，2025 年至 2032 年的複合年成長率為 9.90%。

神經免疫學藥物主要用於治療神經系統和免疫系統疾病。這包括視神經脊髓炎 (NMO)、多發性硬化症 (MS) 和其他自體免疫疾病等神經系統疾病。該領域的許多神經系統疾病被歸類為自體免疫疾病，是指免疫系統錯誤識別並攻擊神經系統組成部分（例如多發性硬化症 (MS) 中的髓鞘）而發生的疾病。

神經免疫學藥物市場-市場動態

神經免疫疾病發生率不斷上升

神經免疫疾病的盛行率不斷上升，推動著神經免疫藥物市場的成長。隨著診斷數量的增加，對有效治療的需求也隨之增加，導致需要藥物的患者群體不斷擴大。這種需求的成長促使製藥公司大力投資研發，從而推動了創新和新藥的開發。不斷成長的患者群體需要更廣泛的治療選擇，促使科學家探索新的治療策略和先進的藥物前景。因此，這些疾病盛行率的上升與市場規模的擴大成正比，因為越來越多的患者尋求並需要神經免疫藥物，從而推動了市場的成長。

神經免疫學藥物市場-細分分析：

全球神經免疫學藥物市場根據產品類型、適應症和地區進行細分。

根據產品類型，市場分為六大類：單株抗體、小分子、淋巴球、重組蛋白、細胞激素和其他產品類型。單株抗體通常用於治療多發性硬化症 (MS) 和視神經脊髓炎 (NMO) 等神經免疫疾病，從而改善病情，因此單株抗體細分市場預計將快速成長。這些單株抗體旨在減輕發炎並抑制發炎反應，或許能夠延緩病程並防止復發。發炎是許多神經免疫疾病的主要因素，單株抗體有助於緩解疼痛並防止神經組織進一步受損。某些單株抗體可以阻止自體免疫系統攻擊髓鞘等神經系統元件，有助於預防神經損傷。

根據適應症，市場分為九類：多發性硬化症、阿茲海默症、重症肌無力症、格林巴利症候群、巴金森氏症、視神經脊髓炎譜系障礙、肌萎縮性側索硬化症、慢性發炎性脫髓鞘多發性神經根神經病變和其他適應症。多發性硬化症 (MS) 是神經免疫學藥物市場上最常見的神經系統疾病之一，預計該領域在預測期內將以最快的複合年成長率成長。在多發性硬化症 (MS) 這種自體免疫疾病中，免疫系統錯誤地攻擊了包裹中樞神經系統 (CNS) 神經纖維的保護性髓鞘層。這種疾病會導致各種各樣的神經系統症狀。此外，由於正在進行的研究，新的治療方法正在被開發，現有的藥物正在被重新用於治療多發性硬化症，這些尖端治療的目標是獲得更好的結果和更多的治療選擇。

神經免疫學藥物市場-地理洞察

預計亞太地區將在預測期內佔據最大的市場佔有率，因為多發性硬化症、視神經脊髓炎和其他自體免疫神經系統疾病等神經免疫疾病在亞太地區日益增加。由於治療方案的改進、早期發現以及對神經免疫疾病認知的提高，每個國家和地區的盛行率都各有不同。一些地區政府正在努力改善神經免疫疾病的管理，包括資助研究、擴大醫療基礎設施以及鼓勵早期發現和介入。

由於北美地區神經免疫學相關藥物臨床試驗的普及，預計在預測期內的複合年成長率最高。北美擁有強大的醫療保健體系、研究機構和多樣化的患者群體，是開展臨床研究的理想之地。美國食品藥物管理局 (FDA) 和加拿大衛生部是兩大監管機構，負責確保神經免疫學藥物的安全性和有效性，並建立了明確的藥品核准監管框架。在北美，許多患者擁有醫療保險，這有助於降低自付治療費用，並改善神經免疫學藥物的可近性。

神經免疫學藥物市場-競爭格局：

神經免疫藥物市場競爭激烈，多家主要參與者爭奪市場佔有率。 Biogen、Hoffmann-La Roche Ltd、T3D Therapeutics 和 Novartis AG 等大型製藥公司處於領先地位，大力投資研發，致力於將創新療法推向市場。這些公司通常擁有針對各種神經免疫疾病的多樣化藥物組合。規模較小的生物技術公司和新興企業也在為市場做出貢獻，其中許多專注於特定的治療領域或新型藥物開發策略。推動競爭的因素包括藥物療效、安全性、定價策略以及獲得監管部門批准和市場准入的能力。在這個動盪的市場中，合作、夥伴關係和收購是常見的策略，因為各公司都在尋求多元化產品組合併鞏固其市場地位。

目錄

第 1 章：神經免疫學藥物市場概述

  • 研究範圍
  • 市場估計年限

第 2 章：執行摘要

  • 市場片段
    • 神經免疫學藥物市場按產品類型細分
    • 神經免疫學藥物市場片段（按適應症）
    • 神經免疫學藥物市場（按國家/地區）
    • 神經免疫學藥物市場按地區分類
  • 競爭洞察

第3章：神經免疫學藥物主要市場趨勢

  • 神經免疫學藥物市場促進因素
    • 市場促進因素的影響分析
  • 神經免疫學藥物市場限制
    • 市場限制的影響分析
  • 神經免疫藥物市場機遇
  • 神經免疫學藥物市場未來趨勢

第4章：神經免疫學藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：神經免疫學藥物市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：神經免疫學藥物市場格局

  • 2024年神經免疫學藥物市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：神經免疫藥物市場－依產品類型

  • 概述
    • 按產品類型分類的細分市場佔有率分析
    • 單株抗體
    • 小分子
    • 淋巴球
    • 重組蛋白
    • 細胞因子
    • 其他產品類型

第 8 章：神經免疫藥物市場 - 按適應症

  • 概述
    • 按適應症分類的細分市場佔有率分析
    • 多發性硬化症
    • 阿茲海默症
    • 重症肌無力
    • 格林-巴利綜合症
    • 帕金森氏症
    • 視神經脊髓炎譜系障礙
    • 肌萎縮側索硬化症
    • 慢性發炎性脫髓鞘多發性神經根神經病變
    • 其他適應症

第9章：神經免疫學藥物市場－按地區分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美神經免疫藥物主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按產品類型）
    • 北美市場規模及預測（依指標）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲神經免疫藥物主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模和預測（按產品類型）
    • 歐洲市場規模及預測（依指標）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區神經免疫藥物主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依產品類型）
    • 亞太地區市場規模及預測（依指標）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲神經免疫藥物主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依產品類型）
    • 拉丁美洲市場規模及預測（依指標）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲神經免疫藥物主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依產品類型）
    • MEA 市場規模及預測（依適應症）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 10 章：關鍵供應商分析-神經免疫學藥物產業

  • 競爭基準化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司簡介
    • Biogen
    • Hoffmann-La Roche Ltd
    • T3D Therapeutics
    • Novartis AG
    • Johnson & Johnson
    • Celgene Corp
    • Merck KGaA
    • Eisai Co Ltd
    • Sanofi
    • Actelion Pharmaceuticals Ltd
    • ImmunoBrain Checkpoint
    • Lundbeck, Eli Lilly
    • AstraZeneca
    • UCB SA
    • AB Science SA
    • AstronauTx, Genetech Inc
    • Inflammasome Therapeutics
    • TauRX Therapeutics Ltd
    • Others

第 11 章：360 度分析師視角

第 12 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5605

Neuroimmunology Drugs Market size was valued at US$ 25,815.10 Million in 2024, expanding at a CAGR of 9.90% from 2025 to 2032.

Neuroimmunology drugs are primarily used to treat neurological and immune system disorders. This includes neurological conditions such as neuromyelitis optica (NMO), multiple sclerosis (MS), and other autoimmune diseases. Many neurological disorders in this area are classified as autoimmune illnesses, which occur when the immune system misidentifies and attacks nervous system components, such as the myelin sheath in multiple sclerosis (MS).

Neuroimmunology Drugs Market- Market Dynamics

Increasing incidence of neuroimmunological disorders

The increasing prevalence of neuroimmunological disorders is driving market growth in the neuroimmunology drugs sector. As diagnoses rises the demand for effective treatments, resulting in a larger patient pool who require medication. This increased demand encourages pharmaceutical companies to invest heavily in R&D, which drives innovation and the development of new drugs. The growing patient population necessitates a broader range of therapeutic options, prompting scientists to investigate novel strategies and advanced drug prospects. As a result, the increasing prevalence of these disorders is directly proportional to increased market size, as more patients seek and require neuroimmunology drugs, driving market growth.

Neuroimmunology Drugs Market- Key Insights

Our research analyst estimates that the global market will grow at a CAGR of approximately 9.90% between 2025 and 2032.

Monoclonal antibodies are expected to have the highest market share in 2025.

Multiple sclerosis is the leading indication segment in 2025.

Asia Pacific is projected to generate the most revenue in 2025.

Neuroimmunology Drugs Market- Segmentation Analysis:

The Global Neuroimmunology Drugs Market is segmented on the basis of Product Type, Indications, and Region.

The market is divided into six categories based on product type: Monoclonal Antibodies, Small Molecules, Lymphocytes, Recombinant Protein, Cytokines, and Other Product Types. Monoclonal antibodies are commonly used as disease-modifying treatments for neuroimmunological conditions such as multiple sclerosis (MS) and neuromyelitis optica (NMO), so the monoclonal antibody segment is expected to grow rapidly. These mAbs, which aim to reduce inflammation and suppress the inflammatory response, may be able to slow the course of the illness and prevent relapses. Inflammation is a major factor in many neuroimmunological illnesses, and monoclonal antibodies can help to relieve pain and prevent further nerve tissue damage. Certain mAbs prevent the autoimmune system from attacking nervous system elements such as the myelin sheath, thereby aiding in the prevention of neurological damage.

The market is divided into nine categories based on Indications: Multiple Sclerosis, Alzheimer's Disease, Myasthenia Gravis, Guillain-Barre Syndrome, Parkinson's Disease, Neuromyelitis Optica Spectrum Disorder, Amyotrophic Lateral Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, and Other Indications. Multiple sclerosis (MS) is one of the most common neurological disorders in the market for neuroimmunology medications, and the segment is expected to grow at the fastest CAGR during the forecast period. The immune system incorrectly attacks the protective myelin layer that envelops nerve fibers in the central nervous system (CNS) in multiple sclerosis (MS), an autoimmune disease. This illness causes a wide range of neurological symptoms. Furthermore, as a result of ongoing research, novel treatments are being developed and existing medications are being repurposed for the treatment of multiple sclerosis, with the goals of these cutting-edge treatments being better results and more treatment options.

Neuroimmunology Drugs Market- Geographical Insights

Asia Pacific is expected to have the largest market share during the forecast period, as neuroimmunological diseases such as multiple sclerosis, neuromyelitis optical, and other autoimmune nervous system illnesses have become more common in the Asia Pacific region. Each country and region has a unique precise prevalence as a result of improved treatment options, early detection, and increased awareness of neuroimmunological illnesses. Several regional governments are working to improve neuroimmunological disease management. This includes funding for research, expanding the healthcare infrastructure, and encouraging early detection and intervention.

North America is expected to have the highest CAGR over the forecast period, owing to the prevalence of clinical trials for neuroimmunology-related medications in the region. It's a desirable location for clinical research due to its strong healthcare system, research institutes, and diverse patient population. The United States Food and Drug Administration (FDA) and Health Canada are two regulatory bodies that ensure the safety and efficacy of neuroimmunology medications, establishing a well-defined regulatory framework for drug approval. In North America, many patients have health insurance, which can help to reduce out-of-pocket treatment costs and improve access to neuroimmunology medications.

Neuroimmunology Drugs Market- Competitive Landscape:

The neuroimmunology drugs market is competitive, with several key players vying for market share. Major pharmaceutical companies such as Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, and Novartis AG are leading the way, investing heavily in R&D to bring innovative treatments to market. These companies frequently have a diverse portfolio of drugs that target various neuroimmunological disorders. Smaller biotechnology companies and emerging players are also contributing to the market, with many focusing on specific therapeutic areas or novel drug development strategies. Factors driving competition include drug efficacy, safety profiles, pricing strategies, and the ability to obtain regulatory approvals and market access. Collaborations, partnerships, and acquisitions are common strategies in this volatile market, as companies seek to diversify their product portfolios and strengthen their market positions.

Recent Developments:

In June 2023, Roche announced that it had signed a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company owned by Roivant Sciences Ltd. and Pfizer Inc. Telavant's RVT-3101 will be developed, manufactured, and commercialised in the United States and Japan under the terms of the agreement.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biogen
  • Hoffmann-La Roche Ltd
  • T3D Therapeutics
  • Novartis AG
  • Johnson & Johnson
  • Celgene Corp
  • Merck KGaA
  • Eisai Co Ltd
  • Sanofi
  • Actelion Pharmaceuticals Ltd
  • ImmunoBrain Checkpoint
  • Lundbeck, Eli Lilly
  • AstraZeneca
  • UCB SA
  • AB Science S.A
  • AstronauTx, Genetech Inc
  • Inflammasome Therapeutics
  • TauRX Therapeutics Ltd
  • Others

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies
  • Small Molecules
  • Lymphocytes
  • Recombinant Protein
  • Cytokines
  • Other Product Types

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY INDICATIONS- MARKET ANALYSIS, 2019 - 2032

  • Multiple Sclerosis
  • Alzheimer's Disease
  • Myasthenia Gravis
  • Guillain-Barre Syndrome
  • Parkinson's Disease
  • Neuromyelitis Optica Spectrum Disorder
  • Amyotrophic Lateral Sclerosis
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Other Indications

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroimmunology Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroimmunology Drugs Market Snippet by Product Type
    • 2.1.2. Neuroimmunology Drugs Market Snippet by Indications
    • 2.1.3. Neuroimmunology Drugs Market Snippet by Country
    • 2.1.4. Neuroimmunology Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroimmunology Drugs Key Market Trends

  • 3.1. Neuroimmunology Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroimmunology Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroimmunology Drugs Market Opportunities
  • 3.4. Neuroimmunology Drugs Market Future Trends

4. Neuroimmunology Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroimmunology Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neuroimmunology Drugs Market Landscape

  • 6.1. Neuroimmunology Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroimmunology Drugs Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Monoclonal Antibodies
    • 7.1.3. Small Molecules
    • 7.1.4. Lymphocytes
    • 7.1.5. Recombinant Protein
    • 7.1.6. Cytokines
    • 7.1.7. Other Product Types

8. Neuroimmunology Drugs Market - By Indications

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indications, 2024 & 2032 (%)
    • 8.1.2. Multiple Sclerosis
    • 8.1.3. Alzheimer's Disease
    • 8.1.4. Myasthenia Gravis
    • 8.1.5. Guillain-Barre Syndrome
    • 8.1.6. Parkinson's Disease
    • 8.1.7. Neuromyelitis Optica Spectrum Disorder
    • 8.1.8. Amyotrophic Lateral Sclerosis
    • 8.1.9. Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    • 8.1.10. Other Indications

9. Neuroimmunology Drugs Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Neuroimmunology Drugs Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Neuroimmunology Drugs Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.7. UK
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. UK Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.8. France
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. France Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.9. Italy
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. Italy Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.10. Spain
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Spain Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.11. The Netherlands
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. The Netherlands Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. Sweden Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.13. Russia
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Russia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.14. Poland
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Poland Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.15. Rest of Europe
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Rest of the Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Neuroimmunology Drugs Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.6. China
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.6.4. China Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. India Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.11. Indonesia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Indonesia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.12. Thailand
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Thailand Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Neuroimmunology Drugs Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Neuroimmunology Drugs Key Manufacturers in Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.7. UAE
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. UAE Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. UAE Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Neuroimmunology Drugs Industry

  • 10.1. Competitive Benchmarking
    • 10.1.1. Competitive Dashboard
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Biogen
    • 10.2.2. Hoffmann-La Roche Ltd
    • 10.2.3. T3D Therapeutics
    • 10.2.4. Novartis AG
    • 10.2.5. Johnson & Johnson
    • 10.2.6. Celgene Corp
    • 10.2.7. Merck KGaA
    • 10.2.8. Eisai Co Ltd
    • 10.2.9. Sanofi
    • 10.2.10. Actelion Pharmaceuticals Ltd
    • 10.2.11. ImmunoBrain Checkpoint
    • 10.2.12. Lundbeck, Eli Lilly
    • 10.2.13. AstraZeneca
    • 10.2.14. UCB SA
    • 10.2.15. AB Science S.A
    • 10.2.16. AstronauTx, Genetech Inc
    • 10.2.17. Inflammasome Therapeutics
    • 10.2.18. TauRX Therapeutics Ltd
    • 10.2.19. Others

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us